CN1850067A - 一种注射用体内供氧溶液及其制备方法和应用 - Google Patents
一种注射用体内供氧溶液及其制备方法和应用 Download PDFInfo
- Publication number
- CN1850067A CN1850067A CN 200610054804 CN200610054804A CN1850067A CN 1850067 A CN1850067 A CN 1850067A CN 200610054804 CN200610054804 CN 200610054804 CN 200610054804 A CN200610054804 A CN 200610054804A CN 1850067 A CN1850067 A CN 1850067A
- Authority
- CN
- China
- Prior art keywords
- injection
- supply solution
- invivo oxyger
- solvent
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007924 injection Substances 0.000 title claims abstract description 135
- 238000002347 injection Methods 0.000 title claims abstract description 135
- 239000000243 solution Substances 0.000 title claims abstract description 99
- 238000000034 method Methods 0.000 title description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 35
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 53
- 239000003814 drug Substances 0.000 claims description 46
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 42
- 229940079593 drug Drugs 0.000 claims description 35
- 239000007788 liquid Substances 0.000 claims description 35
- 239000002904 solvent Substances 0.000 claims description 29
- 238000003756 stirring Methods 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000008215 water for injection Substances 0.000 claims description 14
- 239000002738 chelating agent Substances 0.000 claims description 10
- 229910052751 metal Inorganic materials 0.000 claims description 10
- 239000002184 metal Substances 0.000 claims description 10
- 239000003607 modifier Substances 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 8
- 238000010790 dilution Methods 0.000 claims description 8
- 239000012895 dilution Substances 0.000 claims description 8
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 239000011521 glass Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000005352 clarification Methods 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims 7
- 239000003610 charcoal Substances 0.000 claims 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 30
- 239000001301 oxygen Substances 0.000 abstract description 30
- 229910052760 oxygen Inorganic materials 0.000 abstract description 30
- 239000012155 injection solvent Substances 0.000 abstract 1
- 229940090044 injection Drugs 0.000 description 114
- 150000002978 peroxides Chemical class 0.000 description 77
- 238000012360 testing method Methods 0.000 description 31
- 239000000523 sample Substances 0.000 description 29
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 22
- 229940093181 glucose injection Drugs 0.000 description 21
- 239000000843 powder Substances 0.000 description 18
- 238000001914 filtration Methods 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000008354 sodium chloride injection Substances 0.000 description 12
- 206010021143 Hypoxia Diseases 0.000 description 9
- 239000003708 ampul Substances 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000012982 microporous membrane Substances 0.000 description 7
- 239000013618 particulate matter Substances 0.000 description 7
- 238000010998 test method Methods 0.000 description 7
- 206010002660 Anoxia Diseases 0.000 description 6
- 241000976983 Anoxia Species 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 230000007953 anoxia Effects 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 210000004969 inflammatory cell Anatomy 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 231100000915 pathological change Toxicity 0.000 description 6
- 230000036285 pathological change Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 239000002510 pyrogen Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229940078916 carbamide peroxide Drugs 0.000 description 4
- 229960004106 citric acid Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 210000004872 soft tissue Anatomy 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 4
- 201000006306 Cor pulmonale Diseases 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- 206010014561 Emphysema Diseases 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 3
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 3
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 235000013877 carbamide Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 239000003978 infusion fluid Substances 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 201000004193 respiratory failure Diseases 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 208000032943 Fetal Distress Diseases 0.000 description 2
- 206010016855 Foetal distress syndrome Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 208000018875 hypoxemia Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000006101 laboratory sample Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 2
- 238000009781 safety test method Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010070538 Gestational hypertension Diseases 0.000 description 1
- 201000005624 HELLP Syndrome Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000005262 decarbonization Methods 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
样品 | 性状与澄明度 | 可见异物 | 不溶性微粒 | pH值 | 无菌检查 | 异常毒性 | 热原 | 含量mg/ml |
实施例1 | 无色澄明液体 | 符合规定 | 符合规定 | 3.91 | 符合规定 | 符合规定 | 符合规定 | 100.7 |
实施例2 | 无色澄明液体 | 符合规定 | 符合规定 | 3.76 | 符合规定 | 符合规定 | 符合规定 | 99.6 |
实施例3 | 无色澄明液体 | 符合规定 | 符合规定 | 3.87 | 符合规定 | 符合规定 | 符合规定 | 100.3 |
实施例4 | 无色澄明液体 | 符合规定 | 符合规定 | 2.98 | 符合规定 | 符合规定 | 符合规定 | 251.5 |
实施例5 | 无色澄明液体 | 符合规定 | 符合规定 | 3.08 | 符合规定 | 符合规定 | 符合规定 | 201.6 |
实施例6 | 无色澄明液体 | 符合规定 | 符合规定 | 3.44 | 符合规定 | 符合规定 | 符合规定 | 150.4 |
实施例7 | 无色澄明液体 | 符合规定 | 符合规定 | 7.61 | 符合规定 | 符合规定 | 符合规定 | 49.6 |
实施例8 | 无色澄明液体 | 符合规定 | 符合规定 | 3.96 | 符合规定 | 符合规定 | 符合规定 | 10.4 |
实施例9 | 无色澄明液体 | 符合规定 | 符合规定 | 3.37 | 符合规定 | 符合规定 | 符合规定 | 19.2 |
样品 | 稀释溶媒 | 稀释倍数 | 澄明度 | 可见异物 | 不溶性微粒 | pH值 | 渗透压 |
实施例1 | 5%葡萄糖注射 | 20 | 无色澄明液体 | 符合规定 | 符合规定 | 4.71 | 337 |
0.9%氯化钠注射液 | 20 | 无色澄明液体 | 符合规定 | 符合规定 | 6.13 | 344 | |
实施例2 | 5%葡萄糖注射 | 20 | 无色澄明液体 | 符合规定 | 符合规定 | 4.64 | 342 |
0.9%氯化钠注射液 | 20 | 无色澄明液体 | 符合规定 | 符合规定 | 6.06 | 341 | |
实施例3 | 5%葡萄糖注射 | 20 | 无色澄明液体 | 符合规定 | 符合规定 | 4.84 | 332 |
0.9%氯化钠注射液 | 20 | 无色澄明液体 | 符合规定 | 符合规定 | 6.31 | 334 | |
实施例4 | 5%葡萄糖注射 | 50 | 无色澄明液体 | 符合规定 | 符合规定 | 4.26 | 309 |
0.9%氯化钠注射液 | 50 | 无色澄明液体 | 符合规定 | 符合规定 | 5.84 | 314 | |
实施例5 | 5%葡萄糖注射 | 40 | 无色澄明液体 | 符合规定 | 符合规定 | 4.19 | 356 |
0.9%氯化钠注射液 | 40 | 无色澄明液体 | 符合规定 | 符合规定 | 5.92 | 371 | |
实施例6 | 5%葡萄糖注射 | 30 | 无色澄明液体 | 符合规定 | 符合规定 | 4.51 | 327 |
0.9%氯化钠注射液 | 30 | 无色澄明液体 | 符合规定 | 符合规定 | 6.12 | 332 | |
实施例7 | 5%葡萄糖注射 | 10 | 无色澄明液体 | 符合规定 | 符合规定 | 5.42 | 355 |
0.9%氯化钠注射液 | 10 | 无色澄明液体 | 符合规定 | 符合规定 | 6.96 | 358 | |
实施例8 | 5%葡萄糖注射 | 2 | 无色澄明液体 | 符合规定 | 符合规定 | 4.24 | 387 |
0.9%氯化钠注射液 | 2 | 无色澄明液体 | 符合规定 | 符合规定 | 5.66 | 380 | |
实施例9 | 5%葡萄糖注射 | 4 | 无色澄明液体 | 符合规定 | 符合规定 | 4.06 | 366 |
0.9%氯化钠注射液 | 4 | 无色澄明液体 | 符合规定 | 符合规定 | 5.41 | 359 |
测定时间 | 0月含量 | 3月含量 | 6月含量 | 6月残余率 |
实施例1 | 100.7mg/ml | 97.3mg/ml | 95.1mg/ml | 94.4% |
实施例2 | 99.6mg/ml | 96.8mg/ml | 94.6mg/ml | 95.0% |
实施例3 | 100.3mg/ml | 97.0mg/ml | 94.4mg/ml | 94.1% |
实施例4 | 251.5mg/ml | 244.7mg/ml | 238.1mg/ml | 94.7% |
实施例5 | 201.6mg/ml | 196.1mg/ml | 193.4mg/ml | 95.9% |
实施例6 | 150.4mg/ml | 144.2mg/ml | 140.6mg/ml | 93.3% |
实施例7 | 49.6mg/ml | 48.2mg/ml | 47.3mg/ml | 95.4% |
实施例8 | 10.4mg/ml | 10.0mg/ml | 9.7mg/ml | 93.2% |
实施例9 | 19.2mg/ml | 18.3mg/ml | 18.0mg/ml | 93.8% |
市售品 | 1.008g/瓶 | 0.953g/瓶 | 0.929g/瓶 | 92.2% |
项目 | 受试药物 | 观察结果 | 对照试验 |
溶血性 | 实施例1 | 各受试药物的试验药管均未见溶血 | 生理盐水管未见溶血,蒸馏水管发生溶血 |
实施例2 | |||
实施例3 | |||
实施例4 | |||
实施例5 | |||
过敏性 | 实施例1 | 各受试药物的各动物均无过敏反应 | 30%蛋清:各动物均发生不同程度的过敏反应 |
实施例2 | |||
实施例3 | |||
实施例4 | |||
实施例5 | |||
血管刺激性 | 实施例1 | 血管无异常,管壁完整,间质未见炎性细胞浸润或其它病变 | 0.9%氯化钠:血管无异常,管壁完整,间质未见炎性细胞浸润或其它病变 |
实施例2 | 血管无异常,管壁完整,间质未见炎性细胞浸润或其它病变 | ||
实施例3 | 血管无异常,管壁完整,间质未见炎性细胞浸润或其它病变 | ||
实施例4 | 血管无异常,管壁完整,间质未见炎性细胞浸润或其它病变 | ||
实施例5 | 血管无异常,管壁完整,间质未见炎性细胞浸润或其它病变 |
样品 | 染料渗出量 x±s(n) | 样品 | 染料渗出量 x±s(n) |
市售品 | 16.14±2.11(10) | 实施例2 | 13.74±2.76(10)** |
葡萄糖注射液 | 0.88±0.39(10) | 实施例3 | 14.08±2.18(9)** |
辅料混合物 | 0.81±0.32(10)* | 实施例4 | 13.59±2.98(10)** |
实施例1 | 13.42±2.57(10)** | 实施例5 | 13.24±2.66(10)** |
组别 | PaO2(mmHg)x±s(n) | PaCO2(mmHg)x±s(n) | SaO2(mmHg)x±s(n) | 不良反应 | |
试验组 | 治疗前 | 54.1±5.2(68) | 76.8±4.7(68) | 72.3±5.4(68) | 3人注射局部有轻微肿痛;未见其它不良反应。 |
治疗后 | 85.1±6.3(68) | 64.9±5.8(68) | 90.3±6.1(68) | ||
对照组 | 治疗前 | 53.7±6.1(64) | 77.9±5.4(64) | 71.6±4.9(64) | 8人注射局部有轻微肿痛,另有1人肿痛较严重;未见其它不良反应。 |
治疗后 | 83.9±5.4(64) | 64.4±4.9(64) | 89.7±5.1(64) |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100548045A CN1850067B (zh) | 2005-09-08 | 2006-02-12 | 一种注射用体内供氧溶液及其制备方法和应用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510098314 CN1732914A (zh) | 2005-09-08 | 2005-09-08 | 一种注射用体内供氧溶液及其制备方法 |
CN200510098314.0 | 2005-09-08 | ||
CN2006100548045A CN1850067B (zh) | 2005-09-08 | 2006-02-12 | 一种注射用体内供氧溶液及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1850067A true CN1850067A (zh) | 2006-10-25 |
CN1850067B CN1850067B (zh) | 2011-03-16 |
Family
ID=37131579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006100548045A Expired - Fee Related CN1850067B (zh) | 2005-09-08 | 2006-02-12 | 一种注射用体内供氧溶液及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1850067B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113546040A (zh) * | 2021-07-14 | 2021-10-26 | 柯铭清 | 一种过氧化碳酰胺非水溶媒注射剂、制备方法和应用 |
CN114773231A (zh) * | 2022-03-30 | 2022-07-22 | 湖南一格制药有限公司 | 过氧化碳酰胺、注射用过氧化碳酰胺制剂及其制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3852210A (en) * | 1972-08-11 | 1974-12-03 | Flow Pharma Inc | Stable liquid detergent concentrates containing active oxygen |
US4895875A (en) * | 1988-06-13 | 1990-01-23 | Church & Dwight Co., Inc. | Stabilized peroxide solutions |
CN100404027C (zh) * | 2004-11-26 | 2008-07-23 | 巴里莫尔制药(通化)有限公司 | 一种注射用过氧化碳酰胺冻干制剂、其制备方法及其用途 |
-
2006
- 2006-02-12 CN CN2006100548045A patent/CN1850067B/zh not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113546040A (zh) * | 2021-07-14 | 2021-10-26 | 柯铭清 | 一种过氧化碳酰胺非水溶媒注射剂、制备方法和应用 |
CN114773231A (zh) * | 2022-03-30 | 2022-07-22 | 湖南一格制药有限公司 | 过氧化碳酰胺、注射用过氧化碳酰胺制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1850067B (zh) | 2011-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1091602C (zh) | 含有麦芽糖糊精和氨基酸的腹膜透析溶液 | |
CN1133426C (zh) | 新的稳定的以扑热息痛为基础的制剂及其制备方法 | |
CN101057846A (zh) | 注射用兰索拉唑及其制备方法 | |
CN107412152A (zh) | 一种盐酸右美托咪定注射液组合物 | |
CN1720978A (zh) | 生脉注射制剂及其制备方法 | |
CN103040740A (zh) | 一种奥硝唑注射液及制备工艺 | |
CN1850067A (zh) | 一种注射用体内供氧溶液及其制备方法和应用 | |
CN1555793A (zh) | 柚皮素及其盐用于制备止咳化痰药物 | |
CN1813697A (zh) | 盐酸特比萘芬阴道凝胶及其制法和质量控制方法 | |
CN1830438A (zh) | 一种维生素c冻干粉针剂的制备方法 | |
CN1686165A (zh) | 药用纳米碳管组合物、制备方法及其应用 | |
CN1732936A (zh) | 尼莫地平乳注射液及制备方法 | |
CN1954811A (zh) | 奥沙利铂静脉注射剂及其制备方法 | |
CN1732914A (zh) | 一种注射用体内供氧溶液及其制备方法 | |
CN101721407B (zh) | 复方盐酸阿替卡因注射液及其制备方法 | |
CN1830455A (zh) | 一种多种微量元素注射液的制备方法 | |
CN1742717A (zh) | 含有氯旨醒的液体药剂及其制备方法 | |
CN1857307A (zh) | 一种液体药剂及其制备方法和用途 | |
CN1923211A (zh) | 一种黄芪甲苷注射液及其制备方法 | |
CN1733209A (zh) | 生脉注射制剂及其制备方法 | |
CN1830434A (zh) | 一种曲克芦丁注射液的制备方法 | |
CN1446225A (zh) | 5′-脱氧-n-(取代氧羰基)-5-氟胞嘧啶及其衍生物、制备方法,和包括该物质作为活性成分的抗癌组合物 | |
CN100341526C (zh) | 一种含有抱茎苦荬菜提取物的制剂及其制备方法 | |
CN1589811A (zh) | 一种药物组合物、其制备方法及其用途 | |
CN107468644A (zh) | 一种左旋奥拉西坦注射剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Ye Xuemei Inventor after: Ren Wuxian Inventor after: Zhang Chunhong Inventor after: Jiang Shuomin Inventor after: Feng Wei Inventor after: Zhou Huaying Inventor before: Zhou Huaying |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHOU HUAYING TO: YE XUEMEI REN WUXIAN ZHANG CHUNHONG JIANG SHUOMIN FENG WEI ZHOU HUAYING |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING YUANYAN MEDICINE TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: ZHOU HUAYING Effective date: 20130115 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 062552 CANGZHOU, HEBEI PROVINCE TO: 101102 TONGZHOU, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130115 Address after: 101102 Beijing city Tongzhou District Bridge Industrial Base Jing Sheng South four Street No. 15 East Central Valley U 20C two Patentee after: Beijing Yuanyan Medical Technology Co., Ltd. Address before: 062552 No. 4, unit 47, building two, No. 2, 405 North China Petroleum, Renqiu, Hebei, China Patentee before: Zhou Huaying |
|
DD01 | Delivery of document by public notice |
Addressee: Beijing Yuanyan Medical Technology Co., Ltd. Document name: Notification of Passing Examination on Formalities |
|
DD01 | Delivery of document by public notice |
Addressee: Beijing Yuanyan Medical Technology Co., Ltd. Document name: Notification to Pay the Fees |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Beijing Yuanyan Medical Technology Co., Ltd. Document name: Notification to Pay the Fees |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Beijing Yuanyan Medical Technology Co., Ltd. Document name: Notification of Termination of Patent Right |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110316 Termination date: 20170212 |